Stoke Therapeutics (NASDAQ:STOK) Upgraded to “Outperform” at TD Cowen

TD Cowen upgraded shares of Stoke Therapeutics (NASDAQ:STOKFree Report) from a market perform rating to an outperform rating in a research report released on Tuesday, MarketBeat.com reports.

STOK has been the topic of several other reports. JPMorgan Chase & Co. increased their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a neutral rating in a report on Tuesday. Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a buy rating in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $14.00 target price on shares of Stoke Therapeutics in a research note on Friday, February 16th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $19.63.

View Our Latest Analysis on STOK

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $10.29 on Tuesday. The company’s 50 day simple moving average is $5.77 and its 200 day simple moving average is $4.92. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $14.00. The firm has a market capitalization of $459.49 million, a P/E ratio of -4.25 and a beta of 0.68.

Insider Transactions at Stoke Therapeutics

In other news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the transaction, the insider now directly owns 6,981 shares of the company’s stock, valued at approximately $33,508.80. The disclosure for this sale can be found here. Insiders sold 37,615 shares of company stock valued at $212,852 over the last quarter. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP increased its stake in Stoke Therapeutics by 514.7% in the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock valued at $1,371,000 after buying an additional 291,443 shares during the last quarter. Trexquant Investment LP increased its stake in Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after buying an additional 79,785 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Stoke Therapeutics in the 2nd quarter valued at $121,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Stoke Therapeutics by 9.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after buying an additional 12,478 shares during the last quarter. Finally, Corton Capital Inc. acquired a new stake in Stoke Therapeutics in the 3rd quarter valued at $58,000.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

See Also

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.